Primary Central Nervous System Lymphomas: Salvage Treatment

  • Michele ReniEmail author
  • Elena Mazza
  • Andrés J. M. Ferreri
Part of the Methods of Cancer Diagnosis, Therapy and Prognosis book series (HAYAT, volume 8)


Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal non-Hodgkin lymphoma (NHL) that arises from the brain parenchyma, eyes, cerebrospinal fluid, meninges or spinal cord without evidence of systemic spread. It has had an increase during last 3 decades, accounting for ∼3% of all CNS malignancies in the United States from 1998 to 2002.


Primary Central Nervous System Lymphoma Salvage Treatment Intrathecal Chemotherapy Salvage Radiotherapy Intraocular Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abrey, L.E., Deangelis, L.M., and Yahalom, J. (1998) Long-term survival in primary CNS lymphoma. J. Clin. Oncol. 16:859–863PubMedGoogle Scholar
  2. Abrey, L.E., Ben-Porat, L., Panageas, K.S., Yahalom, J., Berkey, B., Curran, W., Schultz, C., Leibel, S., Nelson, D., Mehta, M., and DeAngelis, L.M. (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J. Clin. Oncol. 24:5711–5715PubMedCrossRefGoogle Scholar
  3. Altman, J.K., Tellez, C., Chandler, J., Levy, R.M., Getch, C., Cohn, R., Gallot, L., Marymont, M., Grimm, S.A., and Raizer, J.J. (2008) Phase II trial of recurrent primary CNS lymphoma (PCNSL) treated with pemetrexed. 44th ASCO Annual Meeting Proceedings [Abstract]. J. Clin. Oncol. 26:2075CrossRefGoogle Scholar
  4. Arellano-Rodrigo, E., Lopez-Guillermo, A., Bessell, E.M., Nomdedeu, B., Montserrat, E., and Graus, F. (2003) Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur. J. Hematol. 70:219–224CrossRefGoogle Scholar
  5. Bessell, E.M., Graus, F., Lopez-Guillermo, A., Lewis, S.A., Villa, S., Verger E., and Petit, J. (2004) Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 59:501–508PubMedCrossRefGoogle Scholar
  6. Enting, R.H., Demopoulos, A., DeAngelis, L.M., and Abrey, L. (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63:901–903PubMedCrossRefGoogle Scholar
  7. Ferreri, A.J., Reni, M., Foppoli, M., Martelli, M., Pangalis, G.A., Frezzato, M., Cabras, M.G., Fabbri, A., Corazzelli, G., Ilariucci, F., Rossi, G., Soffietti, R., Stelitano, C., Vallisa, D., Zaja, F., Zoppegno, L., Aondio, G.M., Avvisati, G., Balzarotti, M., Brandes, A.A., Fajardo, J., Gomez, H., Guarini, A., Pinotti, G., Rigacci, L., Uhlmann, C., Picozzi, P., Vezzulli, P., Ponzoni, M., Zucca, E., Calligaris-Cappio, F., Cavalli, F. International Extranodal Lymphoma Study Group (IELSG) (2009). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374: 1512–1520PubMedCrossRefGoogle Scholar
  8. Ferreri, A.J., Reni, M., Zoldan, M.C., Terreni, M.R., and Villa, E. (1996) Importance of complete staging in non-Hodgkin’s lymphoma presenting as a cerebral mass lesion. Cancer 77:827–833PubMedCrossRefGoogle Scholar
  9. Ferreri, A.J.M., Reni, M., and Villa, E. (2000) Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann. Oncol. 11:927–937PubMedCrossRefGoogle Scholar
  10. Ferreri, A.J.M., Reni, M., Pasini, F., Calderoni, A., Tirelli, U., Pivnik, A., Aondio, G.M., Ferrarese, F., Gomez, H., Ponzoni, M., Borisch, B., Berger, F., Chassagne, C., Iuzzolino, P., Carbone, A., Weis, J., Pedrinis, E., Motta, T., Jouvet, A., Barbui, T., Cavalli, F., and Blay, J.Y. (2002) A multicenter study of treatment of primary CNS lymphoma for the International Extranodal Lymphoma Study Group. Neurology 58:1513–1520PubMedCrossRefGoogle Scholar
  11. Ferreri, A.J.M., Blay, J.Y., Reni, M., Pasini, F., Spina, M., Ambrosetti, A., Calderoni, A., Rossi, A., Vavassori, V., Conconi, A., Devizzi, L., Berger, F., Ponzoni, M., Borisch, B., Tinguely, M., Cerati, M., Milani, M., Orvieto, E., Sanchez, J., Chevreau, C., Dell'Oro, S., Zucca, E., and Cavalli, F. (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J. Clin. Oncol. 21:266–272PubMedCrossRefGoogle Scholar
  12. Fischer, L., Thiel, E., Klasen, H.A., Birkmann, J., Jahnke, K., Martus, P., and Korfel, A. (2006) Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann. Oncol. 17:1141–1145PubMedCrossRefGoogle Scholar
  13. Gavrilovic, I.T., Hormigo, A., Yahalom, J., DeAngelis, L.M., and Abrey, L.E. (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J. Clin. Oncol. 24:4570–4574PubMedCrossRefGoogle Scholar
  14. Glass, J., Gruber, M.L., Cher, L., and Hochberg, F.H. (1994) Preirradiation MTX chemotherapy of primary central nervous system lymphoma: long term outcome. J. Neurosurg. 81:188–195PubMedCrossRefGoogle Scholar
  15. Herrlinger, U., Brugger, W., Bamberg, M., Küker, W., Dichgans, J., and Weller, M. (2000) PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 54:1707–1708PubMedCrossRefGoogle Scholar
  16. Herrlinger, U., Kuker, W., Uhl, M., Blaicher, H.P., Karnath, H.O., Kanz, L., Bamberg, M., and Weller, M. (2005) NOA-03 Trial of high-dose MTX in primary central nervous system lymphoma: final report. Ann. Neurol. 57:843–847PubMedCrossRefGoogle Scholar
  17. Hottinger, A.F., DeAngelis, L.M., Yahalom, J., and Abrey, L.E. (2007) Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 69:1178–1182PubMedCrossRefGoogle Scholar
  18. Iwamoto, F.M., Schwartz, J., Pandit-Taskar, N., Peak, S., Divgi, C.R., Zelenetz, A.D., Humm, J., and Abrey, L.E. (2007) Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer 110:2528–2534PubMedCrossRefGoogle Scholar
  19. Jahnke, K., Thiel, E., Martus, P., Herrlinger, U., Weller, M., Fischer, L., and Korfel, A. German Primary Central Nervous System Lymphoma Study Group (2006) Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J. Neurooncol. 80:159–165PubMedCrossRefGoogle Scholar
  20. Kiewe, P., Korfel, A., Maza, S., Jahnke, K., Munz, D.L., and Thiel, E. (2006) Penetration of Yttrium-90-labeled ibritumomab tiuxetan (ZevalinTM) into primary CNS lymphoma. 2006 ASH Annual Meeting Abstracts [Abstract] 108:2724Google Scholar
  21. Nguyen, P.L., Chakravarti, A., Finkelstein, D.M., Hochberg, F., Batchelor, T.T., and Loeffler, J.S. (2005) Results of whole brain radiation as salvage of MTX failure for immunocompetent patients with primary central nervous system lymphoma. J. Clin. Oncol. 23:1507–1513PubMedCrossRefGoogle Scholar
  22. O’Brien, P., Roos, D., Pratt, G., Liew, K., Barton, M., Poulsen, M., Olver, I., and Trotter, G. (2000) Phase II multicentre study of brief single-agent MTX followed by irradiation in primary CNS lymphoma. J. Clin. Oncol. 18:519–526PubMedGoogle Scholar
  23. Pels, H., Schmidt-Wolf, I.G., Glasmacher, A., Schulz, H., Engert, A., Diehl, V., Zellner, A., Schackert, G., Reichmann, H., Kroschinsky, F., Vogt-Schaden, M., Egerer, G., Bode, U., Schaller, C., Deckert, M., Fimmers, R., Helmstaedter, C., Atasoy, A., Klockgether, T., and Schlegel, U.(2003) Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J. Clin. Oncol. 21:4471–4473CrossRefGoogle Scholar
  24. Plotkin, S.R., Betensky, R.H., Hochberg, F.H., Grossman, S.A., Lesser, G.J., Nabors, L.B., Chon, B., and Batchelor, T.T. (2004) Treatment of relapsed PCNSL with high-dose methotrexate. Clin. Cancer Res. 10:5643–5646PubMedCrossRefGoogle Scholar
  25. Reni, M., and Ferreri, A.J.M. (2004) Is withdrawal of consolidation radiotherapy an evidence–based strategy in primary central nervous system lymphomas? J. Clin. Oncol. 22:1165–1167PubMedCrossRefGoogle Scholar
  26. Reni, M., Ferreri, A.J.M., Garancini, M.P., and Villa, E. (1997) Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: Results of a critical review of the literature. Ann. Oncol. 8:227–234PubMedCrossRefGoogle Scholar
  27. Reni, M., Ferreri, A.J.M., and Villa, E. (1999) Second-line treatment for primary central nervous system lymphoma. Br. J. Cancer 79:530–534PubMedCrossRefGoogle Scholar
  28. Reni, M., Ferreri, A.J.M., Guha-Thakurta, N., Blay, J.Y., Dell’Oro, S., Biron, P., and Hochberg, F.H. (2001) The clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int. J. Radiat. Oncol. Biol. Phys. 51:419–425PubMedCrossRefGoogle Scholar
  29. Reni, M., Mason, W., Zaja, F., Perry, J., Franceshi, E., Bernardi, D., Dell’Oro, S., Stelitano, C., Candela, M., Abbadessa, A., Pace, A., Bordonaro, R., Latte, G., Villa, E., and Ferreri, A.J.M. (2004) Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur. J. Cancer 40:1682–1688PubMedCrossRefGoogle Scholar
  30. Reni, M., Zaja, F., Mason, W., Perry, J., Mazza, E., Spina, M., Bordonaro, R., Ilariucci, F., Faedi, M., Corazzelli, G., Manno, P., Franceschi, E., Pace, A., Candela, M., Abbadessa, A., Stelitano, C., Latte, G., and Ferreri, A.J.M. (2007) Temozolomide as salvage treatment in primary brain lymphomas. Br. J. Cancer 96:864–867PubMedCrossRefGoogle Scholar
  31. Rodriguez, M.A., Cabanillas, F.C., Hagemeister, F.B., McLaughlin, P., Romaguera, J., Swan, F., and Velasquez, W.S. (1995) A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann. Oncol. 6:609–611PubMedGoogle Scholar
  32. Rubenstein, J.L., Fridlyand, J., Abrey, L., Shen, A., Karch, J., Wang, E., Issa, S., Damon, L., Prados, M., McDermott, M., O’Brien, J., Haqq, C., and Shuman, M. (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J. Clin. Oncol. 25:1350–1356PubMedCrossRefGoogle Scholar
  33. Ruhstaller, T.W., Amsler, U., and Cerny, T. (2000) Rituximab: active treatment of central nervous system involvement by non-Hodgkin’s lymphoma? Ann. Oncol. 11:374–375PubMedCrossRefGoogle Scholar
  34. Shapiro, W.R., Young DF, Mehta BM. (1975) Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293: 161–166PubMedCrossRefGoogle Scholar
  35. Soussain, C., Suzan, F., Hoang-Xuan, K., Casasnovas, O., Dupriez, B., Taksin, A.L., Souleau, B., Kolb, B., Jaccard, A., Zini, J.M., Choquet, S., Witz, F., Janvier, M., and Leblond, V. (2001) Results of intensive chemotherapy followed by hematopietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J. Clin. Oncol. 19:742–749PubMedGoogle Scholar
  36. Soussain, C., Hoang-Xuan, K., Taillandier, L., Fourme, E., Choquet, S., Witz, F., Casasnovas, O., Dupriez, B., Souleau, B., Taksin, A.L., Gisselbrecht, C., Jaccard, A., Omuro, A., Sanson, M., Janvier, M., Kolb, B., Zini, J.M., and Leblond, V. (2008) Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J. Clin. Oncol. 26:2512–2518PubMedCrossRefGoogle Scholar
  37. Tyson, R. M., Siegal, T., Doolittle, N.D., Lacy, C., Kraemer, D.F., and Neutwelt, E.A. (2003) Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk. Lymphoma 44:627–633PubMedCrossRefGoogle Scholar
  38. Velasquez, W.S., McLaughlin, P., Tucker, S., Hagemeister, F.B., Swan, F., Rodriguez, M.A., Romaguera, J., Rubenstein, E., and Cabanillas, F. (1994) ESHAP Ð an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J. Clin. Oncol. 12:1169–1176PubMedGoogle Scholar
  39. Voloschin, A.D., Betensky, R., Wen, P.Y., Hochberg, F., and Batchelor, T. (2008) Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J. Neurooncol. 86:211–215PubMedCrossRefGoogle Scholar

Copyright information

© Springer Netherlands 2011

Authors and Affiliations

  • Michele Reni
    • 1
    Email author
  • Elena Mazza
    • 1
  • Andrés J. M. Ferreri
    • 1
  1. 1.Medical Oncology Unit, Department of OncologySan Raffaele Scientific InstituteMilanItaly

Personalised recommendations